1.    Hsu PY, Hsu CT, Yeh ML, Huang CF, Huang CI, Liang PC, Lin YH, Hsieh MY, Wei YJ, Hsieh MH, Dai CY, Lin ZY, Chen SC, Huang JF*, Yu ML, Chuang WL. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C. Dig Dis Sci. 2019

2.     Yeh ML, Huang CF, Huang CI, Hsieh MY, Hou NJ, Lin IH, Liang PC, Tsai YS, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF*, Yu ML, Chuang WL. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. Kaohsiung J Med Sci. 2019 Oct;35(10):624-632.

3.     Yeh ML, Huang CF, Huang CI, Dai CY, Lin IH1, Liang PC1, Hsieh MH, Lin ZY, Chen SC, Huang JF*, Chen JJ, Yu ML, Chuang WL. Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. PLoS One. 2019 Aug 8;14(8):e0220663.

4.     Tai CM, Yen YC, Bair MJ, Tseng CH, Chang TT, Huang CF, Yeh ML, Dai CY, Chuang WL, Yu ML, Huang JF*. Integrated care for methadone maintenance patients with hepatitis C virus infection. Kaohsiung J Med Sci. 2019 Aug;35(8):501-507.

5.    Lin TY, Yeh ML, Huang CF, Huang CI, Dai CY, Hsieh MH, Chen SC, Huang JF*, Yu ML, Chuang WL. Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies. Eur J Gastroenterol Hepatol. 2019 Feb;31(2):224-229.

6.     Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH*; REAL-C Investigators. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. 2019 Sep;13(5):587-598.

7.    Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Chen KY, Ko YM, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML*. Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir. J Gastroenterol Hepatol. 2019 Aug 1.

8.    Lin CW*, Hsu CC, Hsieh PM, Chen YS, Lo GH, Lin HY, Dai CY, Huang JF, Chuang WL, Chen YL, Yu ML. Axl and autophagy LC3 expression in tumors is strongly associated with clinical prognosis of hepatocellular carcinoma patients after curative resection. Cancer Med. 2019 Jul; 8(7):3453-3463.

9.    Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Wei YJ, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML*. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. BMJ Open. 2019 May 5;9(5):e026703.

10.   Yu ML*, Hung CH, Cheng PN, Bair MJ, Huang YH, Kao JH, Shu SJ, Lee PL, Chen JJ, Chien RN, Peng CY, Lin CY, Hsieh TY, Dai CY, Huang JF, Huang CF, Chuang WL An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naïve chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitution. J Infect Dis. 2019 Apr 8; pii: jiz154.

11.   Huang CF, Hung CH, Cheng PN, Bair MJ, Huang YH, Kao JH, Hsu SJ, Lee PL, Chen JJ, Chien RN, Peng CY, Lin CY, Hsieh TY, Cheng CH, Dai CY, Huang JF, Chuang WL, Yu ML*. An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resitance-associated substitution. J Hepatol. 2019 Apr; 70:E248-E249

12.   Yeh ML, Huang CI, Huang CF, Hsieh MH, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Dai CY, Yu ML*, Chuang WL. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. J Infect Dis. 2019 Apr 8;219(8):1224-33.

13.  Wang CW, Dai CY, Chuang TM, Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Yu ML*, Chuang WL. Fulminant Emphysematous Pancreatic Pseudocyst: Infected with Normal Skin Flora. Am J Med. 2019 Feb;132(2):e41-e2.

14.   Huang CF, Wang SC, Yeh ML, Huang CI, Tsai PC, Lin ZY, Chen SC, Dai CY, Huang JF, Chuang WL, Chen A, Yu ML*. Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication. J Gastroenterol Hepatol. 2019 Jan; 34(1) :249-55.

15.   Yu ML, Hung CH, Huang YH, Peng CY, Lin CY, Cheng PN, Chien RN, Hsu SJ, Liu CH, Huang CF, Su CW, Huang JF, Liu CJ, Kao JH, Chuang WL, Chen PJ, Chen DS. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. J Formos Med Assoc. 2019 Feb;118(2):556-64.

16.   Wu DW, Yang CJ, Tsai JH, Hsiao HH. Anti-tuberculosis agents may be associated with myelodysplastic syndromes. Kaohsiung J Med Sci.2019 Oct;35(10):651-652.

17.   Tsai YF, Yang CI, Du JS, Lin MH, Tang SH, Wang HC, Cho SF, Liu YC, Su YC, Dai CY, Hsiao HH. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study. PeerJ.2019 Sep;7:e7481.

18.  Yeh TJ, Yeh CJ, Liu YC, Hsiao HH. Manual polybrene method for pretransfusion test could overcome the interference of daratumumab therapy in myeloma. Transfusion.2019 Aug;59(8):2751-2752.

19.   Lin MH, Hsiao HH. Promising effects of pazopanib with radiation on an advanced prostate leiomyosarcoma after failure of systemic chemotherapy. Kaohsiung J Med Sci.2019 May;35(5):317-318.

20.   Du JS, Lin CH, Wang HC, Hsiao HH. A case of recurrent angiosarcoma with isolated bone marrow metastasis presented as acute disseminated intravascular coagulation. Kaohsiung J Med Sci.2019 Apr;35(4):244-245.

Go to top